Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study

INTRODUCTION: Adalimumab is effective for maintenance of remission in patients with Crohn’s disease (CD) at a dose of 40 mg subcutaneously every 2 weeks. However, adalimumab is associated with (long-term) adverse events and is costly. The aim of this study is to demonstrate non-inferiority and cost-...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, L J T, Pauwels, R W M, Kievit, W, de Jong, D J, de Vries, A C, Hoentjen, F, van der Woude, C J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259868/
https://www.ncbi.nlm.nih.gov/pubmed/32461297
http://dx.doi.org/10.1136/bmjopen-2019-035326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259868/
https://www.ncbi.nlm.nih.gov/pubmed/32461297
http://dx.doi.org/10.1136/bmjopen-2019-035326

Ejemplares similares